Skip Navigation



JAC Advance Access published online on June 9, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh298
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/1/144    most recent
dkh298v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received December 18, 2003
Revised April 8, 2004
Accepted April 23, 2004

Original article

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

Ronald N. Jones 1*, Holly K. Huynh 2, Douglas J. Biedenbach 2, Thomas R. Fritsche 2, Helio S. Sader 2

1 The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA; Tufts University School of Medicine, Boston, MA, USA
2 The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA

* To whom correspondence should be addressed. E-mail: ronald-jones{at}jmilabs.com.


  Abstract

Objectives: To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem.

Methods: This parenteral compound was studied against recent clinical isolates (2001-2002) from a worldwide organism collection. A total of 902 strains were susceptibility tested by reference methods against doripenem and six to 28 comparators including ertapenem, imipenem and meropenem. The organisms tested included: Enterobacteriaceae (281 strains), Acinetobacter spp. (33), Pseudomonas aeruginosa (35), Stenotrophomonas maltophilia (36), other non-fermenters (22), Haemophilus influenzae (61), Moraxella catarrhalis (33), oxacillin-susceptible staphylococci (39), enterococci (84), streptococci (163), various anaerobes (98), and other Gram-positive species such as Corynebacterium and Bacillus spp. (17).

Results: Against Enterobacteriaceae, the average doripenem MIC90 was 0.03 mg/L (range, ≤0.015-0.25 mg/L). Doripenem was two- to 16-fold more potent than imipenem and comparable to ertapenem and meropenem; all doripenem MIC values with enteric bacilli were ≤4 mg/L. Doripenem was active against Aeromonas (MIC50, 0.03 mg/L), Bacillus spp. (MIC50, 0.03 mg/L) and all tested anaerobic species (MIC range, ≤0.015-4 mg/L), but was less active against S. maltophilia (MIC90, >32 mg/L) and Enterococcus faecium (MIC90, >32 mg/L) among the enterococcal species. Time-dependent bactericidal action was observed for doripenem and broth MIC results were slightly greater when compared to agar MIC results. In pilot testing, the optimal doripenem disc concentration was 10 µg, identical to standardized reagents for other clinically available carbapenems.

Conclusions: Doripenem appears to be a potent carbapenem with a spectrum resembling currently marketed antipseudomonal carbapenems, but with greater activity when tested against some non-fermentative bacillary strains. Continued evaluation of doripenem against isolates resistant to other {beta}-lactams appears to be warranted.

Key Words: Keywords: resistance, broad-spectrum, {beta}-lactams, MBC, susceptibility testing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. L. Crandon, C. C. Bulik, and D. P. Nicolau
In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4352 - 4356.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. G. Naber, L. Llorens, K. Kaniga, P. Kotey, D. Hedrich, and R. Redman
Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis
Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3782 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. A. El Solh and A. Alhajhusain
Update on the treatment of Pseudomonas aeruginosa pneumonia
J. Antimicrob. Chemother., August 1, 2009; 64(2): 229 - 238.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
I. Cirillo, N. Vaccaro, K. Turner, B. Solanki, J. Natarajan, and R. Redman
Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers
J. Clin. Pharmacol., July 1, 2009; 49(7): 798 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Pillar, M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm
In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4388 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Kim, M. A. Banevicius, and D. P. Nicolau
In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2497 - 2502.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. A. Davies, W. Shang, K. Bush, and R. K. Flamm
Activity of doripenem and comparator {beta}-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x
J. Antimicrob. Chemother., March 1, 2008; 61(3): 751 - 753.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. Credito, L. M. Ednie, and P. C. Appelbaum
Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Ikawa, N. Morikawa, N. Urakawa, K. Ikeda, H. Ohge, and T. Sueda
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1395 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
W. A. Krueger, J. Bulitta, M. Kinzig-Schippers, C. Landersdorfer, U. Holzgrabe, K. G. Naber, G. L. Drusano, and F. Sorgel
Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1881 - 1889.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.